[A18-74] Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

Last updated 01.02.2019

Project no.:

Commission awarded on 31.10.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Digestion, metabolism and hormones


Primary hypercholesterolaemia or mixed dyslipidaemia

Result of dossier assessment:

Added benefit neither proven for patients for whom statin therapy is an option nor for patients with intolerance or contraindication to statin therapy


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Project no. Title Status
A15-47 Alirocumab - Benefit assessment according to §35a Social Code Book V Commission completed

Federal Joint Committee (G-BA)

2019-05-02 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.